These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 32879427)

  • 1. The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19.
    Gozzetti A; Capochiani E; Bocchia M
    Leukemia; 2020 Oct; 34(10):2815-2816. PubMed ID: 32879427
    [No Abstract]   [Full Text] [Related]  

  • 2. Ruxolitinib for the treatment of SARS-CoV-2 induced acute respiratory distress syndrome (ARDS).
    Neubauer A; Wiesmann T; Vogelmeier CF; Mack E; Skevaki C; Gaik C; Keller C; Figiel J; Sohlbach K; Rolfes C; Renz H; Wulf H; Burchert A
    Leukemia; 2020 Aug; 34(8):2276-2278. PubMed ID: 32555296
    [No Abstract]   [Full Text] [Related]  

  • 3. The potential of JAK/STAT pathway inhibition by ruxolitinib in the treatment of COVID-19.
    Goker Bagca B; Biray Avci C
    Cytokine Growth Factor Rev; 2020 Aug; 54():51-62. PubMed ID: 32636055
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Holding CoVID in check through JAK? The MPN-approved compound ruxolitinib as a potential strategy to treat SARS-CoV-2 induced systemic hyperinflammation.
    Heidel F; Hochhaus A
    Leukemia; 2020 Jul; 34(7):1723-1725. PubMed ID: 32528040
    [No Abstract]   [Full Text] [Related]  

  • 5. Inhibition of cytokine signaling by ruxolitinib and implications for COVID-19 treatment.
    Yeleswaram S; Smith P; Burn T; Covington M; Juvekar A; Li Y; Squier P; Langmuir P
    Clin Immunol; 2020 Sep; 218():108517. PubMed ID: 32585295
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation.
    La Rosée F; Bremer HC; Gehrke I; Kehr A; Hochhaus A; Birndt S; Fellhauer M; Henkes M; Kumle B; Russo SG; La Rosée P
    Leukemia; 2020 Jul; 34(7):1805-1815. PubMed ID: 32518419
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reply: Calm before the storm: Understanding the role of Janus kinase inhibitors in COVID-19.
    Peterson D; Damsky W; King B
    J Am Acad Dermatol; 2020 Jul; 83(1):e67-e68. PubMed ID: 32344070
    [No Abstract]   [Full Text] [Related]  

  • 8. Selective inhibition of thromboinflammation in COVID-19 by Btk inhibitors.
    Siess W; Hundelshausen PV; Lorenz R
    Platelets; 2020 Nov; 31(8):989-992. PubMed ID: 32892684
    [No Abstract]   [Full Text] [Related]  

  • 9. How COVID-19 affects patients receiving anticytokine and JAK inhibitors in rheumatology and dermatology.
    Jessica Chang TY; Pope JE
    Immunotherapy; 2020 Oct; 12(15):1115-1119. PubMed ID: 32640861
    [No Abstract]   [Full Text] [Related]  

  • 10. Protective role of Bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukaemia and COVID-19.
    Thibaud S; Tremblay D; Bhalla S; Zimmerman B; Sigel K; Gabrilove J
    Br J Haematol; 2020 Jul; 190(2):e73-e76. PubMed ID: 32433778
    [No Abstract]   [Full Text] [Related]  

  • 11. The use of Janus kinase inhibitors in the time of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
    Peterson D; Damsky W; King B
    J Am Acad Dermatol; 2020 Jun; 82(6):e223-e226. PubMed ID: 32278797
    [No Abstract]   [Full Text] [Related]  

  • 12. JAK inhibitors in COVID-19: the need for vigilance regarding increased inherent thrombotic risk.
    Mehta P; Ciurtin C; Scully M; Levi M; Chambers RC
    Eur Respir J; 2020 Sep; 56(3):. PubMed ID: 32631841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imatinib is not a potent anti-SARS-CoV-2 drug.
    Zhao H; Mendenhall M; Deininger MW
    Leukemia; 2020 Nov; 34(11):3085-3087. PubMed ID: 32999432
    [No Abstract]   [Full Text] [Related]  

  • 14. Baricitinib, JAK inhibitors and liver injury: a cause for concern in COVID-19?
    Raschi E; Caraceni P; Poluzzi E; De Ponti F
    Expert Opin Drug Saf; 2020 Oct; 19(10):1367-1369. PubMed ID: 32840116
    [No Abstract]   [Full Text] [Related]  

  • 15. Bringing hospital care closer to patients amidst COVID-19.
    Cordoba R
    Lancet Haematol; 2020 Sep; 7(9):e637. PubMed ID: 32853582
    [No Abstract]   [Full Text] [Related]  

  • 16. [Rationales for using JAK 1/2 inhibitors in severely afflicted patients with COVID-19 pneumonia].
    Hasselbalch HC; Poulsen A; Skov V; Kjær L; Nielsen CH; Poulsen TD
    Ugeskr Laeger; 2020 Jun; 182(25):. PubMed ID: 32584762
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EGFR Tyrosine Kinase Inhibitor-Associated Interstitial Lung Disease During the Coronavirus Disease 2019 Pandemic.
    Chang HL; Chen YH; Taiwan HC; Yang CJ
    J Thorac Oncol; 2020 Aug; 15(8):e129-e131. PubMed ID: 32387581
    [No Abstract]   [Full Text] [Related]  

  • 18. COVID-19 and the newly rediscovered multidisciplinarity.
    Bersanelli M
    Immunotherapy; 2020 Oct; 12(15):1101-1103. PubMed ID: 32957828
    [No Abstract]   [Full Text] [Related]  

  • 19. The allergist/immunologist, the Janus gatekeeper of inflammation, COVID-19 and beyond.
    Bellanti JA; Settipane RA
    Allergy Asthma Proc; 2020 Nov; 41(6):395-396. PubMed ID: 33109305
    [No Abstract]   [Full Text] [Related]  

  • 20. Lupus anticoagulant is frequent in patients with Covid-19.
    Harzallah I; Debliquis A; Drénou B
    J Thromb Haemost; 2020 Aug; 18(8):2064-2065. PubMed ID: 32324958
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.